Aura Biosciences, Inc. (NASDAQ:AURA) Insider Sells $122,374.85 in Stock

Aura Biosciences, Inc. (NASDAQ:AURA) insider Los Pinos Elisabet De sold 15,955 shares of the business’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total value of $122,374.85. Following the sale, the insider now owns 304,692 shares of the company’s stock, valued at approximately $2,336,987.64. This represents a 4.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Los Pinos Elisabet De also recently made the following trade(s):

• On Tuesday, October 29th, Los Pinos Elisabet De sold 9,200 shares of Aura Biosciences stock. The shares were sold at an average price of $10.74, for a total value of $98,808.00.

Aura Biosciences Stock Up 2.1 %

AURA stock traded up $0.16 during midday trading on Tuesday, hitting $7.93. The company’s stock had a trading volume of 109,434 shares, compared to its average volume of 130,195. Aura Biosciences, Inc. has a 12 month low of $6.63 and a 12 month high of $12.38. The firm has a market capitalization of $396.10 million, a price-to-earnings ratio of -4.58 and a beta of 0.30. The company has a 50 day moving average of $8.55 and a two-hundred day moving average of $8.91.

Aura Biosciences (NASDAQ:AURA) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.02. On average, analysts anticipate that Aura Biosciences, Inc. will post -1.66 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on AURA shares. Scotiabank boosted their price objective on shares of Aura Biosciences from $20.00 to $23.00 and gave the company a “sector outperform” rating in a research report on Friday, October 18th. Cowen reissued a “buy” rating on shares of Aura Biosciences in a research report on Friday, October 18th. HC Wainwright reiterated a “buy” rating and set a $22.00 price objective on shares of Aura Biosciences in a research note on Thursday, November 14th. Finally, BTIG Research boosted their price objective on Aura Biosciences from $21.00 to $24.00 and gave the company a “buy” rating in a research note on Friday, October 18th. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Aura Biosciences presently has an average rating of “Buy” and a consensus target price of $23.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. American Century Companies Inc. bought a new position in shares of Aura Biosciences during the 2nd quarter valued at about $119,000. SG Americas Securities LLC bought a new position in shares of Aura Biosciences during the 3rd quarter valued at about $169,000. JPMorgan Chase & Co. grew its holdings in shares of Aura Biosciences by 107.5% in the third quarter. JPMorgan Chase & Co. now owns 53,502 shares of the company’s stock valued at $477,000 after purchasing an additional 27,718 shares in the last quarter. Barclays PLC grew its holdings in shares of Aura Biosciences by 256.5% in the third quarter. Barclays PLC now owns 61,010 shares of the company’s stock valued at $544,000 after purchasing an additional 43,897 shares in the last quarter. Finally, Rhumbline Advisers increased its position in Aura Biosciences by 39.6% in the second quarter. Rhumbline Advisers now owns 63,483 shares of the company’s stock worth $480,000 after purchasing an additional 18,011 shares during the last quarter. Institutional investors own 96.75% of the company’s stock.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.